NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is ...

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...

Many women with two or three breast tumors can get by with lumpectomy surgery instead of having their whole breast removed, a new study suggests. In recent years, more patients with multiple tumors ...

Choosing between a mastectomy and a lumpectomy? Learn the differences in survival rates, recovery times, and common misconceptions to find the right breast cancer surgery for you.